A
Asabys
Asabys is a seed to Series C stage investment firm. It has made 19 investments. 35% of their portfolio is in Healthcare. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Average disclosed round size is $56.4M (across 14 rounds with reported amounts).
Portfolio
19
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
CC
Clara Campàs Moya
Managing Partner and co-founder
JL
Josep Ll. Sanfeliu
Managing Partner and Co-Founder
MV
Montserrat Vendrell
Partner
SS
Sylvain Sachot
Partner
IJ
Isabel Jiménez Bernal
Principal
MM
Maite Malet
Principal
AL
Antonio Limatola
Venture Capitalist
JM
Jose María Fernández
Investment Team Member
JC
Joana Correia
Life Sciences VC
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
31 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| OOriva | Pre-Seed | — | Jan 2026 |
 Qida | Growth | — | Nov 2025 |
 SafeHeal | Series C | $10M | Sep 2025 |
 Deepull | Series C | — | Apr 2025 |
 Augustine Therapeutics | Series A | — | Mar 2025 |
 Quibim | Series A | $50M | Jan 2025 |
| Augustine Therapeutics | Series A | — | Jan 2025 |
 Inbrain Neuroelectronics | Series B | $50M | Oct 2024 |
| AAgomab | Series D | $89M | Oct 2024 |
| Augustine Therapeutics | Seed | — | Jan 2024 |
| AAgomab | Series B | $100M | Oct 2023 |
| AAgomab | Series C | $100M | Oct 2023 |
 Amelia | Growth | $175M | Mar 2023 |
 Orikine Bio | Seed | — | Jan 2023 |
 Sidekick | Unknown | $55M | May 2022 |
| Deepull | Series B | — | Jan 2022 |
| Inbrain Neuroelectronics | Series A | $17M | Mar 2021 |
| AAgomab | Series B | $74M | Jan 2021 |
| Sidekick | Series A | $20M | Oct 2020 |
 Medasense | Series C | $18M | Sep 2020 |
 Ona Therapeutics | Series A | — | Jun 2020 |
| Inbrain Neuroelectronics | Seed | — | Jun 2020 |
| Ona Therapeutics | Series A | — | Jan 2020 |
 Mediktor | Series A | $11M | Jan 2018 |
 Nuage Therapeutics | Seed | — | — |
Page 1 of 2
Top Co-Investors
Asabys Partners23 shared
Sofinnova Partners5 shared
Wellington Management3 shared
Frumtak Ventures3 shared
Ysios Capital3 shared
Caixa Capital Risc3 shared
AdBio partners3 shared
Novo Holdings A/S3 shared
Banco Sabadell3 shared
Dawn Biopharma3 shared
Novator2 shared
Bpifrance2 shared
Fund+2 shared
Gemma Frisius Fund2 shared
PMV2 shared
Jeito Capital2 shared
Novo Capital2 shared
Newton Biocapital2 shared
Eli Lilly and Company2 shared
Last updated: 27 September 2026